The management of patients with patent foramen ovale and stroke

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The management of patients with patent foramen ovale (PFO) and stroke remains uncertain. What is known is that PFO is a very common finding in the general population. The risk of initial and recurrent stroke in individuals with PFO is relatively low. With the advent of transesophageal echocardiography, PFO is more commonly being diagnosed. There are insufficient data to support a benefit of warfarin over aspirin in preventing recurrent stroke in most patients with PFO. In those with PFO and a history of a procoagulant state or deep venous thrombosis, anticoagulation may be indicated after weighing the risks of anticoagulation against potential benefits in preventing recurrent stroke. PFO closure does not guarantee the prevention of future stroke and should be addressed case by case, with consideration of patients for entry into ongoing clinical trials of safety, efficacy, and durability.

Original languageEnglish (US)
Pages (from-to)483-490
Number of pages8
JournalCurrent Treatment Options in Neurology
Volume7
Issue number6
DOIs
StatePublished - Jan 1 2005

Fingerprint

Patent Foramen Ovale
Stroke
Transesophageal Echocardiography
Warfarin
Venous Thrombosis
Aspirin
Clinical Trials
Safety
Population

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

The management of patients with patent foramen ovale and stroke. / Meissner, Irene.

In: Current Treatment Options in Neurology, Vol. 7, No. 6, 01.01.2005, p. 483-490.

Research output: Contribution to journalReview article

@article{939f27603d864afabe626ee4ebab08ef,
title = "The management of patients with patent foramen ovale and stroke",
abstract = "The management of patients with patent foramen ovale (PFO) and stroke remains uncertain. What is known is that PFO is a very common finding in the general population. The risk of initial and recurrent stroke in individuals with PFO is relatively low. With the advent of transesophageal echocardiography, PFO is more commonly being diagnosed. There are insufficient data to support a benefit of warfarin over aspirin in preventing recurrent stroke in most patients with PFO. In those with PFO and a history of a procoagulant state or deep venous thrombosis, anticoagulation may be indicated after weighing the risks of anticoagulation against potential benefits in preventing recurrent stroke. PFO closure does not guarantee the prevention of future stroke and should be addressed case by case, with consideration of patients for entry into ongoing clinical trials of safety, efficacy, and durability.",
author = "Irene Meissner",
year = "2005",
month = "1",
day = "1",
doi = "10.1007/s11940-005-0048-5",
language = "English (US)",
volume = "7",
pages = "483--490",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - The management of patients with patent foramen ovale and stroke

AU - Meissner, Irene

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The management of patients with patent foramen ovale (PFO) and stroke remains uncertain. What is known is that PFO is a very common finding in the general population. The risk of initial and recurrent stroke in individuals with PFO is relatively low. With the advent of transesophageal echocardiography, PFO is more commonly being diagnosed. There are insufficient data to support a benefit of warfarin over aspirin in preventing recurrent stroke in most patients with PFO. In those with PFO and a history of a procoagulant state or deep venous thrombosis, anticoagulation may be indicated after weighing the risks of anticoagulation against potential benefits in preventing recurrent stroke. PFO closure does not guarantee the prevention of future stroke and should be addressed case by case, with consideration of patients for entry into ongoing clinical trials of safety, efficacy, and durability.

AB - The management of patients with patent foramen ovale (PFO) and stroke remains uncertain. What is known is that PFO is a very common finding in the general population. The risk of initial and recurrent stroke in individuals with PFO is relatively low. With the advent of transesophageal echocardiography, PFO is more commonly being diagnosed. There are insufficient data to support a benefit of warfarin over aspirin in preventing recurrent stroke in most patients with PFO. In those with PFO and a history of a procoagulant state or deep venous thrombosis, anticoagulation may be indicated after weighing the risks of anticoagulation against potential benefits in preventing recurrent stroke. PFO closure does not guarantee the prevention of future stroke and should be addressed case by case, with consideration of patients for entry into ongoing clinical trials of safety, efficacy, and durability.

UR - http://www.scopus.com/inward/record.url?scp=28044450645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044450645&partnerID=8YFLogxK

U2 - 10.1007/s11940-005-0048-5

DO - 10.1007/s11940-005-0048-5

M3 - Review article

VL - 7

SP - 483

EP - 490

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 6

ER -